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Abstract
Aims The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection
fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth
differentiation factor 15 (GDF-15) is superior to that of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with
HFmrEF or HFpEF.
Methods and results Heart failure patients with either HFpEF or HFmrEF were included in the study. During their first visit to
the HF unit, serum samples were obtained and stored for later assessment of GDF-15 and NT-proBNP concentrations. Patients
were followed up by the HF unit. The main endpoint was all-cause mortality. A total of 311 patients, 90 (29%) HFmrEF and 221
(71%) HFpEF, were included. Mean age was 72 ± 13 years, and 136 (44%) were women. No differences were found in GDF-15
or NT-proBNP concentrations between both HF groups. During a median follow-up of 15 months (Q1–Q3: 9–30 months), 98
patients (32%) died, most (71%) of cardiovascular causes. Patients who died had higher median concentrations of GDF-15
(4085 vs. 2270 ng/L, P < 0.0001) and NT-proBNP (1984 vs. 1095 ng/L, P < 0.0001). A Cox multivariable model identified
New York Heart Association Functional Class III (P = 0.04), systolic blood pressure (P = 0.01), left atrial diameter (P = 0.03),
age >65 years (P < 0.0001), and GDF-15 concentrations (P = 0.01) but not NT-proBNP as independent predictors of all-
cause mortality. The area under the curve was 0.797 for the basic model including NT-proBNP, and the area under the curve
comparing the overall model was 0.819, P = 0.016 (DeLong’s test). Integrated discrimination improvement index after the in-
clusion of GDF-15 in the model with the mortality risk factors was 0.033; that is, the ability to predict death increased by 3.3%
(P = 0.004). Net reclassification improvement was 0.548 (P < 0.001); that is, the capacity to improve the classification of the
event (mortality) was 54.8%. GDF-15 concentrations were divided in tertiles (<1625, 1625–4330, and >4330 ng/L), and sur-
vival curves were evaluated using the Kaplan–Meier technique. Patients in the highest tertile had the poorest 5 year survival,
at 16%, whereas the lowest tertile had the best survival, of 78% (P < 0.001).
Conclusions Growth differentiation factor 15 was superior to NT-proBNP for assessing prognosis in patients with HFpEF and
HFmrEF. GDF-15 emerges as a strong, independent biomarker for identifying HFmrEF and HFpEF patients with worse
prognosis.
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Introduction
Until recently, heart failure (HF) was classified according left
ventricular ejection fraction (LVEF) in HF with reduced or pre-
served LVEF fraction, although a ‘grey zone’ existed between
both HF phenotypes.1 The 2016 update of the European Soci-
ety of Cardiology guidelines defined a new group, HF with
mid-range EF (HFmrEF), as the HF with an LVEF between
40% and 49% and relevant structural heart disease or ele-
vated concentrations of natriuretic peptides.2 Thus, HFmrEF
shares some characteristics with both HF with preserved EF
(HFpEF) and HF with reduced EF (HFrEF) and defines a group
with an uncertain prognosis.3–6 HF is a condition resulting
from several cardiac processes, such as ischaemia, necrosis,
stretch, neurohormonal activation, volume overload, inflam-
mation, and oxidation, and all these processes have their re-
spective biomarkers. As mentioned, HFpEF and HFmrEF
patients share some characteristics, including elevated natri-
uretic peptide concentrations. For this reason, some studies
have analysed biomarkers other than natriuretic peptides
for improving the prognosis of patients with both HF pheno-
types,7 but results were inconclusive. The lack of clear differ-
ences in the analysed biomarkers and the difficulty in using
some of them in daily practice justifies the search for new
prognostic biomarkers for both HF phenotypes.
Growth differentiation factor 15 (GDF-15), also known as
macrophage inhibitory cytokine-1 and non-steroidal anti-
inflammatory drug-activated gene-1, is a member of the
transforming growth factor-β cytokine superfamily with im-
munosuppressive, anti-apoptotic, and anti-inflammatory
properties. GDF-15 is weakly expressed in healthy human
tissues, with the exception of the placenta. GDF-15 expres-
sion is up-regulated by p53, which in turn is a factor
responding to daily-life stressors, such as inflammation,
hypoxia, and oxidative stress.8 Given the plurality of causes
that increase GDF-15, its circulating concentrations have
been related with an increased risk of all-cause, cardiovas-
cular, and non-cardiovascular mortality, cardiovascular
events such as myocardial infarction, HF hospitalization or
stroke, and major bleeding in atrial fibrillation in community
studies and in patients with stable or acute coronary dis-
ease..9 However, GDF-15 concentrations have been mea-
sured in these studies using different methods, the
designs of which promoted a heterogeneity in GDF-15 con-
centrations that was found to be associated with
adverse outcomes. Recently, a fully automatic
electrochemiluminescence immunoassay has been made
available for clinical use, which will facilitate the measure-
ment of large number of samples with better analytical pre-
cision than associated with previous methods.
The aim of our study was to assess the potential of GDF-
15, measured by a fully automated immunoassay, in
predicting all-cause mortality in a large group of HFmrEF
and HFpEF patients.
Methods
Patients meeting HF diagnosis criteria according the Euro-
pean Society of Cardiology guidelines,2 referred to our HF
unit (HFU) between 2010 and 2015, were included in the
study. Patients were referred after an episode of decompen-
sated HF, either after an emergency room visit for dyspnoea
or hospital admission for HF; in both cases, HF was the final
diagnosis, and all patients were treated with diuretics. All pa-
tients underwent echocardiography and were classified ac-
cording to EF as HFrEF, HFmrEF, or HFpEF. Patients with
reduced EF were excluded from the study. Of all patients in-
cluded, 276 patients had elevated natriuretic peptides [N-ter-
minal pro-brain natriuretic peptide (NT-proBNP) >300 ng/L],
while the remaining 35 patients, despite lower concentra-
tions of NT-proBNP, had relevant structural heart disease
(nine had left ventricular hypertrophy, 17 left atrial enlarge-
ment, and four implanted pacemaker, and five were in atrial
fibrillation). One hundred and fourteen patients had hyper-
tensive cardiomyopathy, 77 ischaemic heart disease, 25 hy-
pertrophic cardiomyopathy, and 83 valve disease. Other
miscellaneous aetiologies were three patients with previous
cancer treatment, two with non-compaction cardiomyopa-
thy, and five with atrial fibrillation, all of whom had mild left
ventricular dysfunction. The remaining two patients had con-
strictive pericarditis.
During the first visit to the HFU, signs and symptoms were
registered and blood was drawn. Serum samples were ob-
tained after centrifugation and stored at 80 °C until analy-
sis. NT-proBNP and GDF-15 were measured by
electrochemiluminescence immunoassays on a Cobas e601
platform (Roche Diagnostics, Basel, Switzerland). The mea-
surement ranges for NT-proBNP and GDF-15 were 5–35 000
and 400–20 000 ng/L, and precision was ≤3.5% and ≤4.9%,
respectively, according to the manufacturer. Values reaching
the top of the concentration ranges were equivalent to the
maximum detectable value (i.e. 35 000 ng/L for NT-proBNP
and 20 000 ng/L for GDF-15). Patients were followed in the
HFU, and all-cause mortality was registered. The study was
conducted in accordance with the principles outlined in the
Declaration of Helsinki. All participants received information
about the study and signed informed consent. The study
was approved by the centre’s ethics committee.
Statistical analyses
Categorical variables were expressed as frequencies and per-
centages. Continuous variables were expressed as mean ±
standard deviation or median (Q1–Q3, first and third quar-
tiles), according to their Gaussian or non-Gaussian distribu-
tion. The statistical differences between groups were
compared using the χ2 test for categorical variables and the
Student’s t-test or the Mann–Whitney U test according to
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the Gaussian or non-Gaussian distribution of the continuous
variables. Survival analysis was performed using proportional
hazards regression models dividing GDF-15 into tertiles. The
proportionality of the risks was tested using Schoenfeld resid-
uals. The survival curves were also evaluated with the
Kaplan–Meier technique for the values of GDF-15 (analysed
by tertiles), and the differences in survival were tested with
the log-rank test. Several variables with known power or
power determined in the univariate analysis to identify out-
comes were entered in the multivariate analysis. Variables
were age, HF aetiology, New York Heart Association (NYHA)
functional class, systolic blood pressure, atrial fibrillation, left
atrial diameter, estimated glomerular filtration rate,
haemoglobin, NT-proBNP, and GDF-15 concentrations. A
backward elimination method was then used to identify inde-
pendent predictors of all-cause mortality. To evaluate the po-
tential value of measured biomarkers in a prediction model of
mortality risk, patients with HFmrEF and HFpEF were consid-
ered together, given the similarities found between both
groups. The potential value of measured biomarkers in a pre-
diction model of mortality risk, which included the indepen-
dent predictors of mortality found in our cohort, as a base
risk multivariable model, in addition to NT-proBNP, was eval-
uated by several methods. The Grønnesby and Borgan
goodness-of-fit test was used to determine if the proposed
model fitted the observed outcome with the expected
Table 1 Main characteristics of all patients and according to left ventricular ejection fraction: mid-range (40–49%) and preserved (≥50%)
All HFmrEF HFpEF
P-valuen = 311 n = 90 n = 221
Age (years) 72 ± 13 67 ± 14 73 ± 12 <0.001
Gender (male) 175 (56%) 66 (73%) 109 (49%) <0.001
Aetiology <0.001
Hypertensive cardiomyopathy 114 (37%) 25 (28%) 89 (40%) 0.038
Ischaemic heart disease 77 (25%) 38 (42%) 39 (18%) <0.001
HCM 25 (8%) 4 (4%) 21 (10%) 0.100
Valve disease 83 (27%) 18 (20%) 65 (29%) 0.089
Miscellaneous 12 (4%) 5 (6%) 7 (3%) 0.339
Hypertension 240 (77%) 65 (72%) 175 (79%) 0.185
Diabetes mellitus 114 (37%) 32 (36%) 82 (37%) 0.797
Dyslipidaemia 150 (48%) 44 (49%) 106 (48%) 0.882
Atrial fibrillation 152 (49%) 34 (38%) 118 (53%) 0.01
Weight (kg) 77 ± 17 78 ± 15 76 ± 17 0.439
BMI (kg/m2) 29 ± 5 28 ± 5 29 ± 6 0.175
Blood pressure (mmHg)
Systolic 131 ± 21 132 ± 20 127 ± 20 0.03
Diastolic 75 ± 11 75 ± 11 75 ± 10 0.818
NYHA-FC
II 188 (60%) 61 (68%) 127 (58%) 0.241
III 123 (39%) 29 (32%) 94 (43%)
eGFR (mL/min/1.73 m2) 59 ± 24 62 ± 25 58 ± 23 0.247
Haemoglobin (g/L) 127 ± 19 128 ± 21 127 ± 18 0.515
NT-proBNP (ng/L) 1346 1362 1315 0.844
(median Q1–Q3) (542–2651) (658–2968) (536–2632)
GDF-15 (ng/L) 2822 2748 2822 0.520
(median Q1–Q3) (1631–4378) (1218–5253) (1695–4176)
Echocardiography
LVEF (%) 58 ± 12 44 ± 3 64 ± 9 <0.001
LVEDD (mm) 50 ± 8 55 ± 7 47 ± 7 <0.001
IVST (mm) 13 ± 3 12 ± 3 14 ± 4 0.01
LAD (mm) 50 ± 10 49 ± 8 51 ± 9 0.104
MR (Grade 3–4) 40 (13%) 10 (11%) 30 (14%) 0.564
msPAP ≥ 40 mmHg 120 (39%) 27 (43%) 93 (52%) 0.223
msPAP (mmHg) 40 ± 16 38 ± 16 40 ± 15 0.789
E/A 1.2 ± 0.7 1.3 ± 0.8 1.2 ± 0.6 0.422
Deceleration time (ms) 221 ± 76 221 ± 84 220 ± 72 0.168
Treatment
ACEIs/ARBs 229 (74%) 77 (86%) 162 (69%) 0.002
Beta-blockers 201 (65%) 75 (83%) 126 (57%) <0.001
Loop diuretics 261 (84%) 68 (76%) 193 (87%) 0.01
MRA 110 (35%) 41 (46%) 69 (31%) 0.01
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; E/A, early (E) mitral inflow
peak/atrial (A) filling peak ratio; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor 15; HCM, hypertrophic
cardiomyopathy; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; IVST, inter-
ventricular septum thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection frac-
tion; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; msPAP, mean estimated systolic pulmonary artery pressure;
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA-FC, New York Heart Association functional class.
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calibration capacity of the model. The concordance index (C-
statistic) checked the discrimination capacity of the model.
The improvement in the discrimination capacity of the model
including the biomarkers was assessed by the integrated dis-
crimination improvement index, which evaluated the changes
in the prediction probabilities of mortality estimated. The net
reclassification improvement, category-free version, was
used to test changes in the prediction of estimated mortality
implying a change from one category to another.10 Finally,
the receiver operating characteristic curve of global mortality
was calculated, comparing GDF-15 and NT-proBNP. A value of
P < 0.05 was considered statistically significant. Statistical
software SPSS Version 24.0 (IBM Corp., Released 2016, IBM
SPSS Statistics for Windows, Version 24.0, Armonk, NY) and
R Version 3.3.2 (R Foundation for Statistical Computing, Vi-
enna, Austria) were used to perform all statistical analyses.
Results
Three hundred and eleven patients were included in the
study, of whom 221 had HFpEF and the remaining 90
HFmrEF; their main characteristics are shown in Table 1. Pa-
tients with HFmrEF were younger and had lower left ventric-
ular EF, more dilated left ventricles, and a higher incidence of
ischaemic heart disease than patients with preserved EF. Of
note, concentrations of GDF-15 [2748 ng/L (HFmrEF) vs.
2822 ng/L (HFpEF)] and NT-proBNP [1362 ng/L (HFmrEF) vs.
1315 ng/L (HFpEF)] did not differ statistically between both
groups of patients (Table 1). During follow-up (median 15
months, Q1–Q3: 9–30 months), 98 (32%) patients died (71%
of cardiovascular causes); the main cause of death was refrac-
tory HF (Table 2). Table 3 shows the comparison of clinical
characteristics of patients who died during follow-up vs. sur-
vivors. Patients who died were older and had lower systolic
blood pressure, a higher incidence of atrial fibrillation, worse
NYHA functional class, and lower eGFR and haemoglobin than
those who survived. Furthermore, they had higher GDF-15
and NT-proBNP concentrations than patients with an
uneventful follow-up: GDF-15: 4085 (inter-quartile range:
2554–6651) ng/L vs. 2254 (inter-quartile range: 1389–3562)
ng/L (±2674 ng/L), P < 0.0001, and NT-proBNP: 3613 ng/L
(±5629 ng/L) vs. 1835 ng/L (±3449 ng/L) expressed as median
and standard deviation, P < 0.0001. Multivariable analyses
identified NYHA Functional Class III (P = 0.04), systolic blood
pressure (P = 0.01), left atrial diameter (P = 0.03), age >65
years (P < 0.0001), and GDF-15 concentrations (P = 0.01)
but not NT-proBNP as independent predictors of all-cause
mortality (Table 4). The area under the curve was 0.797 for
the basic model including NT-proBNP, and the area under
the curve comparing the whole model was 0.819, P = 0.016
Table 2 Causes of death
n (%)
CV death







Renal failure 4 (4.0%)
Aortic aneurism 2 (2.4%)
Vascular surgery 2 (2.4%)
Unknown 7 (7.3%)
AMI, acute myocardial infarction; CV, cardiovascular; CVA, cerebro-
vascular accident.
Table 3 Main characteristics of patients grouped according the oc-
currence of all-cause mortality
Alive Died P-
valuen = 213 n = 98
Gender (male) 119 (44%) 56 (32%) 0.833
Aetiology
Hypertensive cardiomyopathy 78 (37%) 36 (37%) 0.984
Ischaemic 54 (25%) 23 (23%) 0.721
HCM 19 (9%) 6 (6%) 0.399
Valve disease 54 (25%) 29 (30%) 0.432
Miscellaneous 8 (4%) 4 (4%) 1.000
Blood pressure (mmHg)
Systolic 134 ± 22 125 ± 19 0.002
Diastolic 76 ± 12 73 ± 11 0.076
Hypertension 158 (74%) 82 (84%) 0.081
Diabetes mellitus 78 (37%) 36 (37%) 1.000
Dyslipidaemia 104 (49%) 46 (47%) 0.807
Atrial fibrillation 88 (41%) 64 (65%) 0.0001
NYHA-FC
II 137 (64%) 51 (52%) 0.002
III 76 (36%) 47 (48%)
eGFR (mL/min/1.73 m2) 64 ± 23 49 ± 21 0.0001
Haemoglobin (g/L) 129 ± 18 123 ± 19 0.01
NT-proBNP (ng/L) 1095 1984 0.0001
(median Q1–Q3) (145–2188) (880–4852)
GDF-15 (ng/L) 2270 4085 0.0001
(median Q1–Q3) (1403–3596) (2554–6756)
Echocardiography
LVEF (%) 57 ± 12 60 ± 11 0.02
LVEDD (mm) 50 ± 8 49 ± 8 0.455
IVST (mm) 13 ± 3 14 ± 4 0.626
LAD (mm) 48 ± 8 52 ± 10 0.001
MR (Grade 3–4) 24 (11%) 16 (16%) 0.197
msPAP ≥ 40 mmHg 73 (45%) 47 (60%) 0.03
msPAP (mmHg) 38 ± 15 43 ± 16 0.01
E/A 1.1 ± 0.7 1.6 ± 0.9 0.01
Deceleration time (ms) 225 ± 76 198 ± 69 0.734
Treatment
ACEIs/ARBs 160 (75%) 69 (70%) 0.407
Beta-blockers 149 (70%) 52 (53%) 0.004
Loop diuretics 166 (78%) 95 (97%) 0.0001
MRA 65 (30%) 45 (46%) 0.008
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angioten-
sin receptor blockers; BMI, body mass index; E/A, early (E) mitral in-
flow peak/atrial (A) filling peak ratio; eGFR, estimated glomerular
filtration rate; GDF-15, growth differentiation factor 15; HCM, hy-
pertrophic cardiomyopathy; IVST, interventricular septum thick-
ness; LAD, left atrial diameter; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; MR, mi-
tral regurgitation; MRA, mineralocorticoid receptor antagonist;
msPAP, mean estimated systolic pulmonary artery pressure; NT-
proBNP, N-terminal pro-brain natriuretic peptide; NYHA-FC, New
York Heart Association functional class.
2226 A.B. Mendez Fernandez et al.
ESC Heart Failure 2020; 7: 2223–2229
DOI: 10.1002/ehf2.12621
(DeLong’s test). Integrated discrimination improvement index
after the inclusion of GDF-15 in the model with the mortality
risk factors was 0.033; that is, the ability to predict death in-
creased by 3.3% (P = 0.004). Net reclassification improvement
was 0.548 (P < 0.001); that is, the capacity to improve the
classification of the event (mortality) was 54.8%. GDF-15 con-
centrations were divided in tertiles (<1625, 1625–4330, and
>4330 ng/L) and the respective survival compared by
Kaplan–Meier survival curves. Statistically significant differ-
ences in 5 year survival were found among the three groups.
Patients in the highest tertile had the poorest 5 year survival,
at 16%, whereas in the lower tertile, survival was 78% (P <
0.001); survival among patients in the intermediate tertile
(39%) differed statistically from the lower (P = 0.006) and
higher (P < 0.001) tertiles (Figure 1).
Discussion
Our results suggest that GDF-15 is a useful biomarker for
identifying HF patients with non-reduced EF associated with
worse prognosis. Moreover, reduced functional capacity,
low systolic blood pressure, higher left atrial diameter, older
age, and higher GDF-15 concentration were the clinical vari-
ables identified as predictors of mortality. Thus, GDF-15 was
the only biomarker with prognostic value identified in these
patients. Natriuretic peptides are recommended in clinical
practice for assessing the diagnosis of HF independently of
LVEF.2,10 Moreover, they are also recommended for the as-
sessment of prognosis in patients with HFrEF. However, their
predictive value in patients with HFmrEF or HFpEF is less
clear,11 and several factors can account for this controversy.
In the case of NT-proBNP, different cut-off values according
to patient age have been suggested, but this could compli-
cate individual risk evaluation and stratification. Furthermore,
previous studies used different LVEF values to classify pa-
tients with low or preserved EF. In fact, HFmrEF is a very het-
erogeneous group of patients that can include patients with
recovered EF after previous reduced ventricular function
and patients with persistent mild deterioration. In a recent
publication of the Swedish HF registry,12 which divided pa-
tients according to the new HF classification, the prognostic
value of elevated NT-proBNP was maintained independently
of EF. Similarly, increased BNP concentrations, although
lower in patients with HFpEF than in patients with HFrEF,
were also associated with worse prognosis.13 Despite these
results, new biomarkers are now available,14 which can im-
prove prognosis prediction in these patients. Previous studies
have shown that GDF-15 is elevated in HFpEF or HFmrEF pa-
tients to a similar degree as in HFrEF patients.15 Increased
GDF-15 has been shown to be independently associated with
exercise capacity impairment and poor quality of life,16 and
its accuracy has been at least as good as that of NT-proBNP,
all suggesting that the combination of both markers could im-
prove diagnostic power. GDF-15 is secreted from the myocar-
dium in response to various stimuli such as ischaemia, wall
stress, or pressure overload.17 It is also secreted from fibro-
blasts in response to stress stimuli.18 Thus, although the
mechanisms are still unclear, both cardiomyocytes and heart
fibroblasts could be the source of GDF-15 in patients with HF.
Because cardiac hypertrophy and interstitial fibrosis are com-
mon pathological features of HFpEF and HFmrEF, the





NYHA-FC III 1.645 1.013 2.670 0.044
SBP 0.983 0.971 0.996 0.011
LAD 1.020 1.002 1.038 0.031
Age 1.072 1.043 1.102 0.000
GDF-15 per 100 ng/L 1.008 1.003 1.013 0.01
NT-proBNP
per 100 ng/L
1.000 1.000 1.000 0.328
GDF-15, growth differentiation factor 15; GDF-15 per 100 ng/L, risk per each 100 ng/L increase; LAD, left atrial diameter; NT-proBNP, N-
terminal pro-brain natriuretic peptide; NT-proBNP per 100 ng/L, risk per each 100 ng/L increase; NYHA-FC, New York Heart Association
functional class; SBP, systolic blood pressure.
Grønnesby and Borgan test shows a good model calibration: P = 0.769.
Figure 1 Kaplan–Meier curves showing cumulative survival according to
tertiles of growth differentiation factor 15 (GDF-15) concentrations.
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prognostic value of GDF-15 found in these patients is not en-
tirely surprising. Furthermore, GDF-15 is also a marker of in-
flammation and metabolic syndrome frequently seen in
patients with HF. The association of metabolic co-morbidities
such as obesity and diabetes can induce coronary microvas-
cular inflammation. These metabolic changes can increase
cardiomyocyte stiffness because of limited availability of ni-
tric oxide and induce fibrosis because of myocardial infiltra-
tion by activated macrophages. Experimental studies have
also demonstrated that GDF-15 null mice show exacerbated
cardiac hypertrophy in response to pressure overload, sug-
gesting that GDF-15 has antihypertensive properties.17 How-
ever, no significant correlation between serum GDF-15 level
and left ventricular mass index has been found in a recent
study.19 In a recent study of 70 patients with HFpEF, elevated
GDF-15 was associated with higher BNP values and identified
as an independent predictor of adverse cardiovascular out-
comes.20 Similarly to our results, in the study by Lok et al.21
that included patients with advanced HF, GDF-15 was also su-
perior to NT-proBNP in assessing prognosis. However, in that
study, patients were selected according to NYHA Functional
Class III–IV, but no information was provided on their ventric-
ular function status. Unlike other studies, we did not find any
prognostic power for NT-proBNP in patients with HFpEF and
HFmrEF, perhaps because the clinical variables identified as
predictors of worse prognosis are variables tightly correlated
with NT-proBNP concentrations, and consequently, the bio-
marker may have lost statistical significance for predicting
events. However, because GDF-15 is a marker of fibrosis
and inflammation, it may play a more important role in the
pathophysiology of HFpEF and HFmrEF and consequently in
the prognosis of these conditions. Recent studies have also
suggested that a model of several biomarkers may provide
higher prognostic information in HF patients,22 but these
models are expensive and not widely available. Thus, GDF-
15 concentrations add prognostic value to clinical information
and emerge as a new biomarker that may help to assess
prognosis in patients with HF. In our study, we measured
GDF-15 with a fully automatic immunoassay that showed re-
markably low analytical imprecision. In previous studies, GDF-
15 was mainly measured with radioimmunometric23 or
enzyme-linked immunosorbent assays20; these analytical ap-
proaches usually show higher imprecision than fully auto-
mated methods. Indeed, the method we used is developed
on an immunoassay platform available in many clinical labo-
ratories, thus facilitating the transferability of results among
different studies. In conclusion, GDF-15 emerged as an
independent predictor of all-cause mortality in patients with
LVEF > 40%. Furthermore, in our cohort, GDF-15 was supe-
rior to NT-proBNP in the prognostic assessment of patients
with HFpEF and HFmrEF.
Limitations
The low number of patients recruited from a single centre
may be the main limitation of the study. However, it is one
of the largest studies to report the use of GDF-15 for prog-
nostic assessment, and internal validation was applied. De-
spite the fact that patients with preserved or mid-range EF
were analysed together, there were no significant differences
in biomarker concentrations between them. Furthermore,
the cause of HF in our study was heterogeneous, so extreme
care should be taken when interpreting these results.
Clinical perspectives
New biomarkers are needed to identify high-risk patients
with HFmrEF and HFpEF to improve their prognosis. Higher
GDF-15 values are associated with higher mortality in pa-
tients with HFpEF and HFmrEF. However, more studies are
necessary before the implementation of GDF-15 in clinical
practice can be recommended. Our preliminary results should
be corroborated in larger cohorts.
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